Battle Of The Weight-Loss Giants: Eli Lilly Whomps Novo Nordisk
Dec 4, 2024 · Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head-to-head study.
Eli Lilly's Zepbound tops Wegovy in head-to-head weight loss trial
Dec 4, 2024 · Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly...
Zepbound tops Wegovy for weight loss in Eli Lilly study
Dec 4, 2024 · Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.
In new trial, Zepbound bests Wegovy for weight loss - Yahoo
Dec 4, 2024 · Patients who got weekly injections of Zepbound lost an average of 20.2% (50.3 pounds) of their body weight after 72 weeks, compared with an average of 13.7% body weight loss (33.1 pounds) for...
Wegovy vs. Zepbound: New Data Declares a Winner - WebMD
Dec. 4, 2024 – People taking the weight loss drug Zepbound experienced dramatically greater weight loss than competitor Wegovy in the first head-to-head trial. Those who took Zepbound lost on...
Zepbound Bests Wegovy for Weight Loss in New Trial - U.S. News …
Dec 4, 2024 · Patients who got weekly injections of Zepbound lost an average of 20.2% (50.3 pounds) of their body weight after 72 weeks, compared with an average of 13.7% body weight loss (33.1 pounds) for...
Zepbound sheds more weight than Wegovy in trial, Eli Lilly says - NBC News
Dec 4, 2024 · People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a head-to-head clinical trial, Lilly said in a news release Wednesday.
Zepbound tops Wegovy in head-to-head study of weight loss …
Dec 4, 2024 · Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo Nordisk, in a head-to-head randomized controlled trial.
Lilly's Zepbound® (tirzepatide) superior to Wegovy® …
Dec 4, 2024 · On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. i At 72 weeks, Zepbound beat Wegovy on both the primary endpoint and all five key secondary endpoints in this trial of adults living with obesity or overweight with at least one weight-related medical problem and without diabetes.
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity …
Dec 4, 2024 · Volunteers were randomly assigned to weekly shots of either Zepbound or Wegovy and followed for 72 weeks. Investigators assessed percentage weight loss from the study’s baseline measurements as the main measure of efficacy. Secondary endpoints included the share of people in each group that achieved specific thresholds like 10% or 20% weight ...
- Some results have been removed